Design, Synthesis, Antiproliferative Potency and In Silico Studies of Novel Alkynyl Quinazolines as Potential EGFR Inhibitors
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27041738 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Apostolia Gkoutzivelaki und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Organic Chemistry, Department of Chemistry, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece. Hauptthemen laut MEDLINE: Quinazolines, ErbB Receptors, Protein Kinase Inhibitors, Drug Design. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The epidermal growth factor receptor (EGFR) is a highly attractive and promising target for novel anticancer agents, particularly for non-small-cell lung cancer (NSCLC), due to its crucial role in regulating cell survival and proliferation. Despite the development of first-generation reversible inhibitors like Gefitinib and Erlotinib, acquired resistance necessitated the discovery of highly potent irreversible inhibitors effective against drug-resistant mutants. Molecular docking calculations utilizing both EGFR conformations identified five top-ranked compounds (QN012, QN017, QN019, QN022, and QN023) proposed for synthesis and biological evaluation. These in silico studies predicted high inhibitory activity against the active and inactive state of EGFR. Herein, we report the design, synthesis and biological evaluation of novel 4-anilino quinazoline derivatives, bearing various alkynyl substituents at position 6, expected to bind to the hinge Met793 residue of EGFR. The effects of the derivatives on various cancer cell lines in terms of cytotoxic/cytostatic activity, interference with cell cycle phase distribution, and suppression of EGFR phosphorylation set the basis for the design of more potent derivatives.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Organic Chemistry, Department of Chemistry, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
- Institute of Nuclear & Radiological Sciences and Technology, Energy & Safety, National Centre for Scientific Research "Demokritos", 15341 Athens, Greece.
- Institute of Biosciences & Applications, National Centre for Scientific Research "Demokritos", 15341 Athens, Greece.
- Department of Pharmacy, Frederick University, Nicosia 1036, Cyprus.
- Department of Biochemistry and Biotechnology, School of Health Sciences, University of Thessaly, 41335 Larissa, Greece.
ORCID-Profile: Lykourgos Chiniadis, Charalampos Triantis, Athanasios Papakyriakou, Harris Pratsinis
Zitieren
APA
Gkoutzivelaki, A., Triantopoulou, S. I., Chiniadis, L., Komiotis, A., Triantis, C., Komiotis, D., Papakyriakou, A., Pratsinis, H., & Manta, S. (2026). Design, Synthesis, Antiproliferative Potency and In Silico Studies of Novel Alkynyl Quinazolines as Potential EGFR Inhibitors. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27041738
Vancouver
Gkoutzivelaki A, Triantopoulou SI, Chiniadis L, Komiotis A, Triantis C, Komiotis D, et al. Design, Synthesis, Antiproliferative Potency and In Silico Studies of Novel Alkynyl Quinazolines as Potential EGFR Inhibitors. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27041738
BibTeX
@article{Gkoutzivelaki2026,
author = {Gkoutzivelaki, Apostolia and Triantopoulou, Sotiria-Iro and Chiniadis, Lykourgos and Komiotis, Alexandros and Triantis, Charalampos and Komiotis, Dimitri and Papakyriakou, Athanasios and Pratsinis, Harris and Manta, Stella},
title = {Design, Synthesis, Antiproliferative Potency and In Silico Studies of Novel Alkynyl Quinazolines as Potential EGFR Inhibitors},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27041738}
}
EUVIMED